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Abstract Osteoarthritis (OA) is one of the most common
forms of degenerative joint disease and a major cause of pain
and disability affecting the aging population. It is estimated
that more than 20 million Americans and 35 to 40 million
Europeans suffer from OA. Analgesics and non-steroidal anti-
inflammatory drugs (NSAIDs) are the only therapeutic treat-
ment options for OA. Effective pharmacotherapy for OA,
capable of restoring the original structure and function of
damaged cartilage and other synovial tissue, is urgently need-
ed, and research into such disease-modifying osteoarthritis
drugs (DMOADs) is in progress. This is the first of three
reviews focusing on OA therapeutics. This paper provides
an overview of current research into potential structure-
modifying drugs and more appropriately targeted pharmaco-
logical therapy. The challenges and opportunities in this area
of research and development are reviewed, covering the most
up-to-date initiatives, trends, and topics.
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Introduction
The ever-expanding aging population expects and deserves a
fulfilling and active life, with low dependence on “managed
care”. This requires a healthy and well-functioning
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musculoskeletal system. However, age-related musculoskele-
tal diseases are a major cause of global morbidity, and result in
high costs for health and social care systems. Chronic and
inflammatory joint disease is a major cause of disability for the
elderly. As life expectancy increases the incidence of muscu-
loskeletal disease will grow, meaning there is an acute need for
intervention to prevent and treat these diseases.
Advancing age is a major risk factor for degenerative joint
disease. Osteoarthritis (OA) is a disabling degenerative joint
disease that affects more adults than any other rheumatic
disease does, and is the main cause of pain and disability
among the elderly. Prevalence of OA increases with age: the
disease affects 10 % of males and 18 % of females over 45,
and these figures are predicted to rise as the general population
ages. OA causes joint pain, stiffness, and loss of function,
predominantly affecting the knee, hip, hand, spine, and other
weight-bearing joints. A 2005 study in the USA estimated that
OA is one of the five main causes of disability for non-
hospitalized adults (source: Centers for Disease Control and
Prevention (CDC, http://www.cdc.gov/), USA). The National
Institute of Arthritis and Musculoskeletal and Skin Diseases
(NIAMS, http://www.niams.nih.gov/) estimates that more than
20 million Americans suffer from OA. It is expected that by
2030, 20 % of adults in Western Europe and North America
will have OA. Therefore, OA is expected to be a heavy
economic burden on healthcare systems and community
services in Europe and the rest of the world as the population
expands and the number of elderly people increases.
OA is characterized by degeneration of articular cartilage,
low-grade synovial inflammation (synovitis), and alterations to
peri-articular and subchondral bone [1]. Traditionally, OA has
been regarded as a “wear and tear” degenerative joint condi-
tion. However, recent studies have revealed that systemic
factors regulate the metabolism of joint tissue, and that sub-
stantial cross-talk occurs between different joint tissues [2].
This means OA affects the whole joint, including cartilage,
subchondral bone, synovium, tendon, and muscle [3, 4•, 5, 6].
As described earlier, OA is primarily associated with aging.
However there are other important contributing factors, includ-
ing obesity (which increasesmechanical stress), history of joint
trauma or repetitive joint use, genetics, inherited and acquired
metabolic disorders, muscle weakness, underlying anatomical
and orthopedic disorders (e.g. congenital hip dislocation), joint
infection, crystal deposition, previous rheumatoid arthritis, and
a variety of bone turnover and blood clotting disorders. There
is increasing evidence for a connection between metabolic
dysfunction and OA [2, 7]; indeed, metabolic osteoarthritis
has recently been described as a subtype of OA [7].
Prevalence of OA is significantly higher in women, espe-
cially postmenopausal women and women with co-morbid
metabolic bone conditions including osteoporosis (OP) [7].
Although the underlying causes of women’s increased sus-
ceptibility to OA are not fully understood, research is
beginning to focus on associations with sex hormones, obesi-
ty, and physical activity to determine whether modifiable
factors including estrogen, weight management, and protec-
tion during sport and exercise can be used as treatment for
postmenopausal women with OA and OP [2, 8].
OA has an important inflammatory component that includes
increased activity of several cytokines and chemokines in the
joints [9•]. These inflammatory cytokines and chemokines drive
the production and secretion of enzymes that mediate destruc-
tion of cartilage [1]. Cartilage aging drives cellular alterations
that result in a damage-induced, senescence-associated secretory
phenotype characterized by production and secretion of cyto-
kines, chemokines, and proteases [10, 11•]. Oxidative stress and
inappropriate mechanical signals can further promote the
senescence-associated secretory phenotype of aging
chondrocytes [10, 12], as observed in tumor cells [13••].
OA is now regarded as a disease of the whole joint, and this
must be taken into consideration when evaluating new and old
treatments [14]. Our understanding of the pathogenesis of OA
is rapidly increasing and is expected to assist development of
disease-modifying therapy. However, very little new pharma-
cological therapy has been introduced and use of existing
symptom-modifying drugs with deleterious side effects con-
tinues. Limitations of conventional medical management of
OA indicate the need for novel, safe and effective treatment
for OA patients. Current therapy insufficiently addresses clin-
ical need, and there is no effective pharmacological or biolog-
ical therapy capable of restoring the original structure and
function of damaged cartilage and other synovial tissue in
OA or any other form of arthritis. This is the first of three
reviews of recent progress in OA therapeutics. This paper will
address the topic of targeted pharmacological therapy.
Existing Pharmacotherapy for OA
Current pharmacological intervention that addresses chronic
pain in OA is insufficient, and no proven structure-modifying
therapy is available [1]. The main clinical guidelines recom-
mend use of mild analgesics, for example acetaminophen
(paracetamol), for treatment of mild-to-moderate OA symp-
toms, and only recommend use of nonsteroidal anti-
inflammatory drugs (NSAIDs) after acetaminophen has failed
[15]. NSAIDs are the most common treatment for rheumato-
logical conditions including OA, rheumatoid arthritis (RA) and
gout. These drugs are extensively used throughout the world
and have analgesic, antipyretic and, at higher doses, anti-
inflammatory effects. In the UK, almost a quarter of patients
visiting their general practitioner for “arthritic” and “rheumatic”
complaints are prescribed NSAIDs. The trend is similar for
other industrialized nations. NSAIDs relieve pain and increase
mobility for approximately 60% of patients with OA, acting by
inhibiting activity of the cyclooxygenase (COX) enzymes [16].
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There are two isoforms of COX: COX-1, which is constitutive-
ly expressed, and COX-2, which is an inducible isoform. COX-
2 expression is normally low, but is increased by inflammatory
stimuli and cytokines [16]. Animal studies and data from
humans reveal that COX-2 up-regulation in OA and RA is
associated with pain and inflammation [17]. Prostaglandins
synthesized by the constitutively-expressed COX-1 have
“cytoprotective” functions in the stomach and are involved in
maintaining normal physiological function of the stomach lin-
ing. Inhibition of the COX-1 isoform affects these important
homeostatic and gastroprotective functions, and has substantial
consequences for gastrointestinal health [18]. NSAIDs have a
wide variety of side effects, but the most clinically important
are upper gastrointestinal tract dyspepsia, peptic ulceration,
hemorrhage, and perforation, leading to death for some pa-
tients. Most conventional NSAIDs inhibit both COX isoforms.
However, some NSAIDs, including meloxicam [19] and
celecoxib, are more selective towards COX-2 [17]. COX-2-
selective inhibitors provide effective pain relief for patients with
OA and RA, and have similar efficacy to traditional NSAIDs.
However, cost-effectiveness and cost-utility studies suggest that
their use should be limited to patients with severe upper gas-
trointestinal side effects and ulcers [20]. For patients with knee
OA, aceclofenac reduces pain, reduces disease severity, and
improves functional capacity to a similar extent to diclofenac,
piroxicam, and naproxen [21]. As with traditional NSAIDs,
nephrotoxicity and hypertension are concerns with COX-2
inhibitors [22]. Despite their side effects, NSAIDs are recom-
mended by the European League Against Rheumatism
(EULAR, http://www.eular.org/), and the Osteoarthritis
Research Society International (OARSI, http://www.oarsi.
org/) treatment guidelines committee recommends NSAIDs
for management of hip and knee OA [23]. More selective
pharmacotherapy is needed for treatment of OA and related
arthritic conditions.
Should Cartilage or Subchondral Bone be Targeted?
Articular cartilage in load-bearing joints requires a solid and
stable foundation of subchondral bone. There is ongoing debate
about the function of subchondral bone in OA [3, 24–26, 27•].
Although many researchers support the idea that OA is a
disease of articular cartilage, there is increasing support for the
theory that subchondral bone should be a priority target of OA
treatment [26]. It is believed that vascular pathology and loss of
mineral density in subchondral bone are important to initiation
and/or progression of OA [25], and that changes to subchondral
bone may accelerate progression of pre-existing disease [28].
Several recent studies have emphasized the importance of the
cartilage–bone interface in OA, observing that cartilage and
subchondral bone act as a single functional unit in health and
in disease, and that alteration of either tissue, resulting from
injury or abnormal loading, may alter the biomechanical status
of the other. This concept has recently been discussed in detail
by other investigators [3, 24]. Other papers have questioned
whether there is any compelling evidence to suggest that OA
can be modified, and whether the current treatment focus on
articular cartilage is appropriate [29, 30]. Synovitis and abnor-
mal subchondral bone turnover also contribute to disease pro-
gression, and are associated with OA pain [33]. Subchondral
bone is an attractive target for disease-modifying osteoarthritic
drugs (DMOADs) [26]; it is increasingly recognized that OA is
a disease of the whole joint [14, 31], and that the bone–cartilage
unit is especially important [32•].
Bisphophonates and Strontium Ranelate—Linking
Osteoporosis Treatments to OA
Bone remodeling is a continuous process of old bone resorption
and new bone formation. It is a natural, physiologically regu-
lated process, occurring during growth, development, and ad-
aptation to mechanical load and physical exercise. Bone re-
modeling controls the reshaping and replacement of bone after
traumatic injury, for example fracture, and after micro-damage,
which occurs during intensive physical activity. In coordination
with endocrine signals, it responds to the functional demands of
mechanical loading. Imbalanced regulation of bone resorption
and bone formation results in metabolic bone disease, including
osteoporosis (OP) [34]. OP is a bone disease that causes bones
to become more porous, resulting in reduced bone mineral
density and bone mass. This gradually makes bones weaker,
more brittle, and more fragile, with long bones becoming
substantially more prone to fracture. OP results from an imbal-
ance in the bone remodeling process whereby bone resorption,
which is mediated by osteoclasts, outpaces bone formation,
which is mediated by osteoblasts. It can also occur as a conse-
quence of chronic joint disease: for example, subchondral
sclerosis is associated with age-related joint degeneration [35].
The rationale for targeting bone when treating OA is based
on molecular cross-talk between subchondral bone and carti-
lage [32•], and the subchondral bone resorption that occurs at
an early stage in development of OA [46]. Abnormalities of
subchondral bone metabolism, especially increased bone turn-
over, have been detected in the early stages of some forms of
OA [26]. If osteoclastic bone resorption reduces bony support
for the overlying cartilage, this can facilitate progression of OA
[25]. Studies of people with knee OA have observed that
cartilage loss and risk of knee replacement are higher if
subchondral bone cysts are present than if only bone marrow
lesions (BMLs) are present, suggesting that cysts identify those
most likely to benefit from prevention of disease progression
[36]. These studies support the hypothesis that subchondral
bone is important to progression of joint disease, and that
factors which result in cartilage destruction may come from
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subchondral bone [37]. Therefore, strategies for new treatment
to inhibit progression of OA must consider the subchondral
bone compartment [25, 37]. In OP and OA, both high and low
bone mass conditions may result in disease induction and/or
progression [26].
Substantial progress has been made over the last five de-
cades in non-hormonal OP treatment [38]. Bisphosphonates
(BPs) are a class of drugs used to treat OP and related bone
disease by preventing loss of bone mass. They were developed
in the early 1960s as a potential treatment for bone disease. BPs
are the most frequently prescribed drug for treating osteoporo-
sis and other diseases characterized by increased bone resorp-
tion. For patients with postmenopausal OP, BPs reduce osteo-
clast activity to healthy, pre-menopausal levels, reducing the
rate of bone loss. BPs increase bone mass, strengthen bones,
and reduce incidence of fracture, including severe fractures of
the hip and spine. BPs approved for treatment and/or preven-
tion of osteoporosis include alendronate (Fosamax, Fosamax
Plus D; Merck), ibandronate (Boniva; Genentech), zoledronic
acid (Reclast; Novartis), and risedronate (Actonel, Actonel with
Calcium, and Atelvia; Warner Chilcott). Other BPs include
etidronate and raloxifene, used for secondary prevention of
osteoporotic fragility fractures in postmenopausal women. In
addition to treating OP, BPs are also used to reduce calcium
levels in the blood and to treat Paget’s disease of bone (which
causes bones to become weak and deformed) and bone-related
cancer, alleviating pain and weakness. BPs are also used after
other forms of cancer treatment, including chemotherapy and
hormone therapy, both of which can weaken bone. They can
also prevent some cancers spreading to bone. BPs are
an extremely important class of drugs and, in addition to their
therapeutic benefits for OP and related bone disease, are
potential therapeutic agents for disease modification in OA
[39]. They may also lead to new techniques for investigating
the pathogenic mechanisms relating synovitis [4•],
subchondral bone pathology [25, 26], and OA pain [33].
However, it is important to note that mixed results have been
obtained from clinical trials of risedronate. The effect of
risedronate on joint structure and symptoms of knee OA was
studied in the BRISK randomized, controlled trial [40]. The
study was a one-year prospective, double blind, placebo-
controlled study that enrolled patients (40–80 years of age)
with mild to moderate OA of the medial compartment of the
knee. The study concluded that significant improvements of
joint structure and symptoms were observed for patients with
primary knee OA treated with risedronate [40]. A subsequent
multinational trial failed to find any effect on structural out-
comes. The knee OA structural arthritis (KOSTAR) study
tested the efficacy of risedronate for providing symptom relief
and slowing disease progression for patients with knee OA
[41]. This study found that although risedronate reduces bio-
chemical markers of cartilage degradation, it does not reduce
symptoms or slow radiographic progression for patients with
medial compartment OA of the knee. Although these UK-
based studies reported some favorable effects for risedronate
compared with placebo, the cohorts selected included too few
cases of progressive radiographic OA to demonstrate
chondroprotection [42]. Early animal studies indicated that
risedronate should work, as the drug can reduce bone marrow
lesions. However, the animal data did not transfer well to
human subjects. The patients were not properly stratified, and
this could be one reason the trials failed.
Strontium ranelate, a strontium salt of ranelic acid, is a drug
for treating osteoporosis (OP); it is marketed as Protelos or
Protos by the French pharmaceutical company Servier
(http://www.servier.com/). Ranelic acid (molecular formula:
C12H10N2O8S) is an organic acid that chelates metal cations
(Fig. 1). In Europe strontium ranelate has been authorized for
treatment of osteoporosis in postmenopausal women to reduce
the risk of vertebral and hip fracture. Strontium ranelate is a
bone density conservation agent—these drugs inhibit bone
resorption and favor bone extracellular matrix formation and
mineralization. They are used to heal fractures and to treat
metabolic bone diseases, including OP. The drug is unusual
in that it both increases deposition of new bone by osteoblasts
and reduces resorption of bone by osteoclasts. It is therefore
promoted as a “dual action bone agent” (DABA). Strontium
ranelate is registered in many countries as a prescription drug
to reduce the risk of vertebral and hip fracture associated with
postmenopausal OP. In the UK, strontium ranelate is pre-
scribed under the National Health Service (NHS, http://www.
nhs.uk/) for treatment of postmenopausal OP. In addition to the
“fragility fracture risk assessment” pathway (http://pathways.
nice.org.uk/pathways/osteoporosis/osteoporosis-overview),
the National Institute for Health and Clinical Excellence
(NICE, http://www.nice.org.uk/) has published updated final
guidelines for use of alendronate, etidronate, risedronate,
Fig. 1 Molecular structure of strontium ranelate, also known as: Protelos,
135459-87-9, Osseor, Protos, Ranelic acid distrontium salt. Molecular
formula C12H10N2O8SSr2 (molecular weight 517.5214)
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raloxifene, strontium ranelate, and teriparatide in England and
Wales for prevention and treatment of osteoporotic fragility
fractures in postmenopausal women (http://www.nice.org.uk/
nicemedia/live/11748/42472/42472.pdf). In the USA,
strontium ranelate is not approved for treating OP by the US
Food and Drug Administration (FDA, http://www.fda.gov/)
because of safety concerns and reports of increased risk of
blood clots and memory loss. Studies suggest that patients
receiving 2 g day−1 strontium for 3–4 years are at greater risk
of vascular side effects (i.e. blood clots) and nervous system
side effects (seizures). Rizzoli and colleagues recently
reviewed drug–drug interactions for OP patients. These are
relatively rare and although there are risks, these should be
weighed against the benefits of treatment [43].
A systematic review published in 2006 reviewed the litera-
ture on strontium ranelate to determine its efficacy at
preventing and treating postmenopausal OP [44]. The authors
searched the MEDLINE, EMBASE and Cochrane Library
databases from 1996–2005. They also included relevant con-
ference proceedings from the previous two years. The review
included randomized controlled trials (RCTs) of at least one-
year duration comparing strontium ranelate with placebo. Four
trials were included in the review, which provided silver-level
evidence (a term introduced by the Cochrane Musculoskeletal
Group and explained at http://musculoskeletal.cochrane.org/)
for the efficacy of strontium ranelate for both fracture reduction
for postmenopausal women with OP and increasing BMD for
postmenopausal women with or without OP.
A recent clinical trial indicated that strontium ranelate can
slow progression of knee OA, making it the first trial to achieve
a positive result when investigating a drug with potential as a
disease-modifying osteoarthritic drug (DMOAD). The “stron-
tium ranelate efficacy in knee osteoarthritis trial,” or SEKOIA,
published in 2012, suggested the drug can significantly affect
progression of knee OA compared with placebo. In a double-
blind randomized controlled trial, strontium ranelate reduced
knee OA pain symptoms, improved function, and reduced
radiography-detectable cartilage loss, as indicated by reduc-
tions in joint-space narrowing over three years [45•]. The trial
was a phase III, multicenter, international, double-blinded,
placebo-controlled study of men and women 50 years of age
or above with a clinical diagnosis of knee OA as defined by the
American College of Rheumatology (ACR, http://www.
rheumatology.org/). The investigating team’s objective was to
evaluate the efficacy and safety of two doses of strontium
ranelate (1 g and 2 g day−1) versus placebo, administered
orally over three years, for treating people with knee OA. The
primary endpoint of the study was radiographic progression of
knee OA, and assessment of joint space narrowing (JSN)
determined by use of radiography. The main secondary end-
points for the study were the Western Ontario and McMaster
Universities osteoarthritis index (WOMAC, http://www.
rheumatology.org/practice/clinical/clinicianresearchers/
outcomes-instrumentation/WOMAC.asp), used to measure
pain functional assessment of the target knee, and knee pain
intensity assessed during the 48 h before the visit by use of a
visual analogue scale. Treatment with strontium ranelate was
associated with reduced progression of cartilage degradation.
Administration of strontium ranelate (2 g day−1) significantly
reduced total WOMAC score and pain subscore and revealed a
possible trend for improved physical function. The study
concluded that treatment with strontium ranelate is associated
with significant beneficial effects on joint structure for patients
with knee OAwhen the drug is administered at 2 g day−1.
According to the Medicines and Healthcare products Reg-
ulatory Agency (MHRA), an executive agency of the Depart-
ment of Health in the UK responsible for ensuring that med-
icines and medical devices are effective and acceptably safe,
strontium ranelate is not recommended for patients with current
or previous venous thromboembolism (VTE) or for patients
who are temporarily or permanently immobilized (e.g. post-
surgical recovery or prolonged bed rest) and thus at increased
risk of VTE (http://www.mhra.gov.uk/Safetyinformation/
DrugSafetyUpdate/CON152727). The need for continued
treatment with strontium ranelate should also be re-evaluated
for patients over 80 years old who are at risk of VTE. Strontium
ranelate is also associated with serious skin and hypersensitivity
reactions, including drug rash with eosinophilia and systemic
symptoms (DRESS). In addition, rare serious skin reactionsmay
occur during the first weeks of treatment.
The European Medicines Agency (EMA, http://www.ema.
europa.eu/) has completed a review of strontium ranelate.
Although a positive benefit–risk balance has been confirmed
for the drug, new contraindications and revised warnings have
been issued (http://www.ema.europa.eu/docs/en_GB/
document_library/Press_release/2012/03/WC500124206.pdf).
The EMA Committee has concluded that these medicines are
an important treatment for women with osteoporosis, but
changes to prescribing advice are necessary to better manage
associated risks. A European Commission decision on this
opinion is expected in the near future.
Further clinical studies on the efficacy and safety of
bisphosphonates are required to determine whether this drug
is capable of disease modification in OA. Clinical trials on
cohorts of younger OA patients are needed to confirm the
drug’s effects and assess its safety.
Inhibitors of Inducible Nitric Oxide Synthase (iNOS)
Nitric oxide (NO) gas has important biological properties. NO
is a signaling molecule involved in many physiological
and pathological processes. It was initially identified as
endothelium-derived relaxing factor (EDRF) by Robert F.
Furchgott, Louis J. Ignarro, and Ferid Murad, who shared
the 1998 Nobel Prize in Physiology or Medicine for its
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discovery. NO is a free radical synthesized from L-arginine by
the NO synthase enzymes (NOS). It is now well established
that production of NO by iNOS is stimulated by cytokines,
including IL-1β, interferon-γ (IFN-γ), and tumor necrosis
factor-α (TNF-α). These mediators induce iNOS expression
in a variety of cells, including chondrocytes, synoviocytes and
macrophages. NO production is increased in inflammatory
arthritides. Increased NO production is observed in a variety
of compartments in vivo, but inflammatory synovium and
cartilage are the main sources of NO in the joint. Catabolic
and proinflammatory cytokines, NO, prostaglandin E(2)
(PGE2) [5], and neuropeptides [47], produced by the inflamed
synovium in OA [4•], collectively alter the balance of cartilage
matrix degradation and repair, eventually leading to excess
production of the proteolytic enzymes responsible for cartilage
breakdown [48]. Because synovitis is associated with clinical
symptoms of OA and reflects joint degradation in OA, it has
been suggested that synovium-targeted therapy could help al-
leviate symptoms and prevent structural progression [4•].
Induced NO, in addition to being a “final common media-
tor” of inflammation, is essential for induction, up-regulation,
and amplification of inflammatory response [49]. NO is
believed to be involved in cartilage inflammation and catabo-
lism and the pain associated with OA [50], and NO and iNOS
are therefore regarded as potential targets for therapeutic inter-
vention [51]. Onset of arthritis in rodent models has been
successfully blocked by the NOS inhibitor NG-monomethyl-
L-arginine (L-NMMA) [51], suggesting possible involvement
of NO in OA pathogenesis and tissue destruction.
Diacerhein, also known as diacetylrhein, is an anti-
inflammatory drug used in OA treatment. It works by blocking
the action of IL-1β, and is a potent inhibitor of IL-1β-induced
NO production by chondrocytes [52]. A Cochrane Database
systematic review published in 2006 suggested that diacerein
leads to a small, but consistent, improvement of OA pain [53].
The European Medicines Agency (EMA, http://www.ema.
europa.eu/ema/) has initiated a review (http://www.ema.
europa.eu/docs/en_GB/document_library/Referrals_
document/Diacerein/Procedure_started/WC500135576.pdf)
of diacerein-containing medicines used to treat the symptoms
of OA and other joint diseases. This action is in response to
evidence from clinical trials and scientific literature
suggesting that the efficacy of diacerein against OA is weak.
The EMA will review the data on the benefits and risks of
diacerein and issue an opinion on the marketing authorization
of diacerein-containingmedicines across the European Union.
Emerging evidence suggests that NO and its redox de-
rivatives may also have protective functions in the joint
[50]. For example, in culture models of chondrocytes, ad-
dition of exogenous NO inhibits proinflammatory activa-
tion by preventing nuclear localization of the transcription
factor nuclear factor-κB (NF-κB). In contrast, the presence
of peroxynitrite, a redox derivative of NO, increases the
inflammatory response of chondrocytes by sustaining nuclear
localization of NF-κB [50]. Additionally, under some condi-
tions, exogenous NO can stimulate collagen synthesis in
cultured rat fibroblasts and human tendon cells. The protective
functions of NO for multiple cell types, with the opposing
activity in cultured chondrocytes suggest that NO may have
additional protective effects for chondrocyte function.
Metabolic Targets: Mitochondria
Mitochondrial diseases are believed to be caused by the failure
of mitochondria. Mitochondria dysfunction has been implicat-
ed in age-related diseases and the aging process [54].
Chondrocytes age as the extracellular matrix of cartilage un-
dergoes age-dependent changes. Consequently, the biosynthet-
ic activity of chondrocytes declines, and their responsiveness to
anabolic mechanical stimuli and growth factors decreases [55].
There is increasing interest in the effect of mitochondrial ab-
normalities associated with aging and mitochondrial dysfunc-
tion on OA [56, 57]. Degradation of mitochondrial DNA and
loss of the mitochondrial membrane potential may affect path-
ogenesis of OA, especially because respiration-mediated ATP
production and mitochondrial function are sensitive to nitric
oxide (NO) and are vital for matrix synthesis [58].
Mitochondrial functions, including mitochondrial respira-
tory chain activity and ATP synthesis, have been observed to
be altered in OA chondrocytes [59•]. Francisco Blanco’s
research team revealed that respiratory activity of OA
chondrocytes is altered as a result of the reduced activity of
mitochondrial complexes II and III [60].
Somatic mutations of mitochondrial DNA (mtDNA) have
been described in synoviocytes from RA joints [61]. Studies of
chondrocytes from OA joints suggest there is also mitochon-
drial dysfunction in OA and, as for RA, this may originate
from somatic mutations in mtDNA [62, 63]. Polymorphisms in
mtDNA could be useful biomarkers for the diagnosis and
prognosis of OA [59•]. Studies are in progress to determine
whether these mutations induce inflammatory damage in RA
andOA, or whether they are epiphenomena of cellular damage
induced by the proinflammatory cytokines, prostaglandins,
reactive oxygen species (ROS), and nitric oxide (NO) of
chronic inflammatory joint disease. It is known that
proinflammatory cytokines, including TNF-α and IL-1β, reg-
ulate mitochondrial function in human articular chondrocytes
by reducing the activity of the mitochondrial respiratory chain
and reducing ATP levels [55]. The mitochondrion is strongly
affected by proinflammatory cytokine-mediated toxicity in
chondrocytes [63]: progressive ATP depletion caused by NO
release in chondrocytes reduces mitochondrial reserves
[64]. This NO-mediated mitochondrial dysfunction [55]
suggests that targeting NO production and iNOS might
support mitochondrial function in chondrocytes. Maintaining
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mitochondrial DNA integrity is an important potential preven-
tive measure that might protect bioenergetic processes in
chondrocytes from the effects of NO, IL-1β and TNF-α
[63]. However, it is difficult to conceive how mitochondria
could be targeted for therapeutic purposes.
ROS, for example superoxide, hydrogen peroxide, and
hydroxyl radicals, are usually produced in mitochondria when
electrons leak from the electron-transport chain and react with
oxygen to form superoxide. ROS levels are controlled via
multiple enzyme systems, including superoxide dismutase
(SOD), catalase, glutathione S-transferase and thioredoxin.
Production of hydrogen peroxide (H2O2) by inflammatory
and synovial cells is an important cause of cellular damage
during joint inflammation. Hydrogen peroxide is formed by
dismutation of superoxide and by oxidases. SOD converts
superoxide to hydrogen peroxide, which is then removed by
glutathione peroxidase or catalase, preventing formation of
such highly aggressive ROS as peroxynitrite or the hydroxyl
radical [65]. Living cells maintain a complex and interrelated
protective system, involving endogenous antioxidant vita-
mins, use of minerals including selenium and manganese as
cofactors, and glutathione, to protect themselves from the
harmful effects of ROS [66, 67]. Chondrocytes use a variety
of antioxidant enzymes, including catalase, SOD and a variety
of peroxidases, to reduce and control cellular levels of ROS.
Recent work from David Young’s group has revealed that
SOD is downregulated during OA progression and in end-
stage disease [68]. Depletion of SOD in chondrocytes in-
creases ROS levels [68]. This work confirms observations
made by Francisco Blanco’s group several years earlier [69].
Ruiz-Romero et al. [69] used a proteomics approach, based on
two-dimensional DIGE and MALDI-TOF–TOF mass spec-
trometric identification of mitochondria-enriched protein frac-
tions, to reveal a “redox imbalance” and reduced mitochon-
drial SOD levels in chondrocytes from OA cartilage.
In summary, a decline in mitochondrial function is believed
to be important to the aging process and to aging-associated
disease [54].Mitochondrial dysfunction and DNA damage are
implicated in the pathogenesis of OA [56, 59•, 63]. As carti-
lage ages, the cells and their organelles also undergo age-
related changes and the number of chondrocytes declines
[70, 71]. Mitochondrial dysfunction increases the inflamma-
tory response to cytokines [72], induces COX-2 expression (at
both mRNA and protein levels) [73] and is accompanied by
oxidative stress, chondrocyte apoptosis, cytokine-induced
chondrocyte inflammation and matrix catabolism, and
chondrocalcinosis [58, 59•, 64]. Multiple factors are believed
to contribute to mitochondrial dysfunction in OA [74]. These
include inhibition of mitochondrial biogenesis via suppression
of important mitochondrial transcription factors. Risk of mi-
tochondrial dysfunction is increased for individuals with spe-
cific mitochondrial DNA haplotypes [75] and by acquired
mitochondrial DNAmutations [59•, 61]. These mitochondrial
changes, combined with defective chondrocyte autophagy,
result in increased ROS and reduced endogenous antioxidants,
and promote inflammatory responses, abnormal gene expres-
sion, and cell death [74].
A sedentary lifestyle, associated with OA-induced physical
inactivity, is associated with reduced mitochondrial function
[57]. Therefore, from a metabolic perspective, physical activity
and an active lifestyle are potentially important preventive
measures against OA [57]. Development of drugs and identifi-
cation of naturally occurring compounds capable of altering
mitochondrial function could complement strategies to reduce
cartilage degradation in OA [63]. Regulating chondrocyte me-
tabolism, autophagy (an essential, homeostatic and protective
mechanism bywhich cells degrade their own components), and
apoptosis (programmed cell death) may be achieved via phar-
macological and physiological modulation of sirtuins. Sirtunins
are a family of seven NAD(+)-dependent deacetylases, activat-
ed by NAD(+) and the antioxidant phytochemical resveratrol
[76•]. Resveratrol has been revealed to protect chondrocytes
against oxidant injury and apoptosis via its effect on mitochon-
drial repolarization and ATP production [77]. The author has
recently reviewed the potential benefits of resveratrol for en-
hancing chondrocyte function [78, 79]. Dietary supplementa-
tion with resveratrol and related antioxidant phytochemicals
may be an important nutritional preventive strategy for OA,
especially for people with compromised antioxidant systems.
Anti-MMP Therapy
Enzymatic breakdown of collagen in articular cartilage is
mainly mediated by matrix metalloproteinases (MMPs) [48].
MMPs are extracellular proteinases involved in cleavage of
ECM components [80] and of proteins on the cell surface and
in pericellular regions [81]. The MMPs identified to date can
be grouped by their substrate specificity [82], and include
collagenases (MMP-1, MMP-8, MMP-13, MMP-18),
gelatinases (MMP-2, MMP-9), stromelysins (MMP-3, MMP-
10, MMP-11), matrilysins (MMP-7, MMP-26), membrane
type-MMPs (the MT-MMPs: MMP-14, MMP-15, MMP-16,
MMP-17, MMP-24 and MMP-25), and several others (MMP-
12, MMP-19,MMP-20, MMP-21,MMP-22, MMP-23,MMP-
27 and MMP-28). More than 27 MMPs have been identified.
Four of these, the collagenases MMP-1, MMP-8, and MMP-
13, and the membrane-bound MMP-14, are important to carti-
lage collagen destruction [86]. MMP-13 has a substrate prefer-
ence for type II collagen, and is believed to be the most
important collagenase in cartilage [87]. It can also act as a
gelatinase, enabling it to degrade collagen further than other
collagenases do. The synthesis and activity of MMPs in carti-
lage and other joint tissue are tightly controlled by a variety of
pro-inflammatory cytokines, growth factors, and tissue inhibi-
tors. MMPs are secreted as inactive pro-enzymes and are
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usually activated by other proteinases. Inhibition occurs both
locally (by tissue inhibitors of metalloproteinases (TIMPs)) and
systemically (by α2-macroglobulin) [83–85]. In joint disease,
increased expression of collagenolytic MMPs and reduced
expression of their endogenous regulatory inhibitors, the
TIMPs, disrupts the homeostatic balance between synthesis
and destruction to favor collagen breakdown. This mechanism
causes the extensive damage to the collagen fibrillar network
observed in OA cartilage pathology which seems to be medi-
ated primarily by the collagenases MMP-1 and MMP-13 [88].
The author has recently discussed MMP inhibitors in
a review article published in Current Drug Targets [48].
Specific areas of interest within this topic are TIMPs,
small molecule MMP inhibitors (MMPIs), antibody in-
hibitors (to be covered in greater detail in the second
review in this series), anti-sense technology, and dietary
phytochemical inhibition of MMPs (previously reviewed
by the author in this journal [79]).
Mapp and co-workers studied the effects of M503902—an
orally administeredMMP inhibitor developed byAstraZeneca,
with broad activity against a range of MMPs—on joint pathol-
ogy, osteochondral angiogenesis, chondropathy, and pain in a
rat meniscal transection (MNX) model of OA [89]. The au-
thors found that treatment with the MMP inhibitor reduced
weight-bearing asymmetry, attenuated chondropathy, and re-
duced vascularity. The authors propose that the association
between osteochondral angiogenesis and pain may be
explained by perivascular nerve growth or stimulation of
subchondral nerves after loss of osteochondral integrity. The
authors conclude that targeting angiogenesis may be useful for
treatment of pain associated with OA structural damage.
Several herbal medicines have been investigated for anti-
inflammatory and indirect MMP-inhibitory properties. These
medicines include phytochemicals and flavonoids and cate-
chins from green tea, rosehip, curcumin, and resveratrol
(discussed in the section “Herbal therapy for OA” and
reviewed in Ref. [48]).
The involvement of MMPs in normal physiological pro-
cessesmeans that therapy involving total inhibition is clinically
undesirable. However, partial inhibition of over-active MMPs
may be beneficial when treating inflammatory conditions.
Selective modulation to upregulate, activate, or downregulate
targeted MMPs is a more appropriate objective. However,
there has been no major new development in this area.
Herbal Therapy for OA
There is growing interest in herbal drugs andmedicines, and the
patient-driven search for alternative treatments and herbal med-
icines has intensified. There is substantial overlap between
conventional and herbal medicine in treatment of arthritic,
rheumatic, and musculoskeletal disease: some of the drugs in
our pharmacopoeia (or their derivatives) have a long-
established history in ethnopharmacology and have been used
for centuries [79]. Detailed discussion of this topic is beyond
the scope of this article. The author has recently reviewed this
area of research in a review article published in Current Rheu-
matology Reports [79]. The author has also reviewed the
potential prophylactic properties of plant-derived phytochemi-
cals, including curcumin and resveratrol, and their use for
targeting NF-κB signaling and inflammation in OA [78]. Avail-
able clinical data for resveratrol are encouraging and support
its inclusion in future clinical trials [90]. Other researchers have
reviewed the topic of herbal medicine and nutraceuticals for
OA [91–96]. This area of research is constantly growing and
expanding. Herbal remedies and botanical supplements have
become important topics of research and clinical practice in
orthopedics and rheumatology [94]. Many herbal medicines
seem to be relatively safe, with some having an encouraging
risk–benefit profile, and may offer a much-needed alternative
for patients with OA [97]. Some herbal remedies are inhibitors
of NF-κB, and may be able to reduce use of NSAIDs and the
associated side effects. However, in-vivo data and large, ran-
domized clinical trials to verify the theoretical reasons for
using herbal medicine are largely lacking [79]. The author’s
view is that herbal medicine could have benefits if used to
supplement existing pharmaceutical treatment options [98]
with the objective of reducing dosages and frequency of con-
sumption of conventional drugs.
Lessons from Recent Setbacks and Failures
The ability to develop new drugs to slow progression of OA in
the elderly population will have enormous public health im-
plications [99]. However, the pharmaceutical industry is cur-
rently suffering from a productivity crisis, and there are very
few new drugs approaching clinical readiness. Over the last
decade the number of new compounds has decreased; how-
ever, more IND applications to the Food and Drug Adminis-
tration (FDA) have been made over the last ten years than
during the previous decade. This reveals the current state of
the industry: the processes of discovery and preclinical devel-
opment are highly productive, but very few compounds make
it through the subsequent clinical evaluation phase. This trend
has implications for the future of OA clinical trials and
DMOAD development.
The pharmaceutical industry has had to learn from several
failures and setbacks. The key points are summarized below:
& Developing drugs that target enzymes involved in physi-
ological, in developmental, and in pathological functions
(e.g. MMPs) can be extremely challenging.
& Biological approaches were largely ignored and regarded
as the domain of small start-up biotechnology companies,
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many of which were acquired by larger drug companies in
the last few years. Biological therapy will be covered in
the next paper in this series.
& It is difficult to test new drugs without sensitive bio-
markers to help monitor patient response. The lack of such
markers necessitates identification of a range of biochem-
icals that can be used to assess the efficacy of new
formulations.
New Biomarkers to Stimulate Drug Discovery
A biomarker is a characteristic that is objectively measured
and evaluated as an indicator of normal biological process-
es, pathogenic processes, or pharmacological responses to a
therapeutic intervention [100]. OA is often diagnosed via
radiography when clinical signs of pain and loss of mobil-
ity have already appeared. Unfortunately, despite being a
leading technique, radiography has numerous weaknesses.
It is an indirect measure of alterations in articular cartilage
and does not measure a dynamic process. Changes ob-
served over time are small, and occur in only a subset
(progressors) of patients. Radiographs rarely correlate with
symptoms and are poorly reproducible. By the time radio-
graphic changes have been detected, disease has progressed
extensively and cartilage degradation is quite substantial.
OA is characterized by a prolonged pre-clinical “molecular”
phase, a “pre-radiographic” phase, and a “recalcitrant radio-
graphic” phase; by the latter phase there is already exten-
sive structural change to joints, along with pain and loss of
function. This is why more advanced imaging techniques,
for example MRI, are more suitable for detecting early
degenerative changes in the joint.
In 2011 the Osteoarthritis Research Society International
(OARSI, http://www.oarsi.org/) and the US Food and Drug
Administration (FDA, http://www.fda.gov/) established the
OARSI FDA osteoarthritis biomarkers working group
[101••]. This working group has divided OA biomarkers
into two major groups: soluble or “wet” biomarkers and
“dry” biomarkers [101••]. These biomarkers will facilitate
earlier diagnosis and treatment. Linking a biomarker to a
clinical endpoint can greatly assist the drug-discovery process.
We have very few reliable biomarkers for OA, and more
research is needed to identify markers that link to dynamic
changes in the joint. In the future, biomarkers will be increas-
ingly important in all the different phases of OA drug devel-
opment, including regulatory review. However, only a small
number of biomarkers are expected to become sufficiently
accepted and established to serve in regulatory decision-
making as surrogate endpoints substituted for traditional clin-
ical endpoints [102]. Drug and biomarker development are
interdependent, and future progress in OA drug discovery will
require sensitive new biomarkers to predict OA progression
and responses to new therapeutics.
Conclusions
There is an urgent need for new treatment options for
patients suffering from OA. The pharmaceutical industry
has tried and failed to provide effective and safe disease-
modifying osteoarthritic drugs (DMOADs) for the millions
of patients suffering from this debilitating disease [103].
Future therapeutics will probably require a combination of
approaches. It seems unlikely that any single treatment
will suffice for OA because of its complex etiology and
multifactorial nature. Future therapy needs to be highly
targeted and personalized, rather than the “one drug to
treat all forms” model that has dominated thus far. Dietary
and lifestyle intervention will need to be used alongside
new DMOADs for treating OA as a global and systemic
joint disease. In addition, OA pain needs to be addressed
by use of a combinatorial approach or by beginning
DMOAD treatment at a much earlier stage, before any
symptoms have appeared. However, this will be extremely
challenging to achieve because patients do not present
before the occurrence of pain.
For decades OA has been viewed as a “wear and tear”
disease leading to loss of cartilage. This concept is increasingly
Fig. 2 Schematic diagram
summarizing current concepts in
pharmacological treatment of OA
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being challenged, as is the potentially misleading terminolo-
gy—e.g. “osteoarthrosis”—used to describe the “wear and
tear” [104••]. Instead, OA is increasingly viewed as a “low
grade” inflammatory disease [104••]. The “low grade” inflam-
mation is believed to be induced by obesity, metabolic syn-
drome, innate immunity, and aging-related inflammation,
supporting emerging arguments for the inflammatory theory
of OA [104••].
These concepts reveal the need for a more radical, compre-
hensive, and biology-based approach to studying OA, as has
been emphasized by Qvist et al. [103], and the need for new
analytical tools, reagents, and technology to help us study the
metabolic processes and molecular changes underlying the
structural alterations of OA [105, 106].
Diagnosis of OA is usually on the basis of clinical and
radiography changes, which occur during quite late-stage
disease and have poor sensitivity for monitoring disease pro-
gression [107]. This means OA is diagnosed during its irre-
versible stages, when treatment can be expected only to re-
duce pain and slow progression. This is a major disadvantage
for drug development. The focus of DMOAD development
must shift toward validation of biochemical and imaging
biomarkers [108]: biomarkers might provide relevant infor-
mation more rapidly than imaging techniques (i.e. radiogra-
phy and MRI) [107]. Finally, emerging evidence suggests that
OA is a disease of the whole joint, affecting many of its
musculoskeletal components, including articular cartilage,
tendons, muscles, ligaments, subchondral bone, and even
adipose tissue [3, 31, 32•, 109]. DMOAD development will
need to consider the contribution of each of these joint com-
ponents to the disease.
This paper has focused on better-targeted pharmacological
therapy. The main targets discussed are summarized in Fig. 2.
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